戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Here we describe a 'catch-and-release' mechanism that am
2                                              Here we describe a broadly applicable technique called '
3                                              Here we describe a cubic host obtained from the self-ass
4                                              Here we describe a detailed protocol based on covalent b
5                                              Here we describe a detailed protocol that describes how
6                                              Here we describe a discovery platform that can identify
7                                              Here we describe a dual inhibitor of the bromodomain and
8                                              Here we describe a flow cytometry workflow to determine
9                                              Here we describe a flow system comprised of two function
10                                              Here we describe a form of metabolism linking anoxygenic
11                                              Here we describe a GWAS using a highly multiplexed aptam
12                                              Here we describe a long-sought route through ribose amin
13                                              Here we describe a measurement platform that allows for
14                                              Here we describe a mechanism for transmitting a chemical
15                                              Here we describe a medicinal chemistry program starting
16                                              Here we describe a method - Freestyle Fluidics - that ov
17 n oncogenes under tissue-specific promoters, here we describe a method that allows for the precise op
18                                              Here we describe a microfluidic DNA preconcentration tec
19                                              Here we describe a microfluidics-based strategy to spin
20                                              Here we describe a molecular device that couples CRISPR-
21                                              Here we describe a molecular system that can be programm
22                                              Here we describe a multinational drug discovery programm
23                                              Here we describe a natural experiment involving deterior
24                                              Here we describe a new member of this group, Xandarella
25                                              Here we describe a new method for neuronal labelling by
26                                              Here we describe a new mouse strain, in which human inte
27                                              Here we describe a new software tool, RNAModMapper (RAMM
28                                              Here we describe a new, exquisitely three-dimensionally
29                                              Here we describe a novel homogeneous fluorescence intens
30                                              Here we describe a novel osteoadsorptive bisphosphonate-
31                                              Here we describe a novel real-time quantitative PCR (qPC
32                                              Here we describe a panel of genetic screens to identify
33                                              Here we describe a parasite-specific transcription facto
34                                              Here we describe a phosphoproteomics workflow to examine
35                                              Here we describe a physiologically relevant model for st
36                                              Here we describe a platform for identifying target-bindi
37                                              Here we describe a previously unappreciated contribution
38                                              Here we describe a protocol to generate expandable and m
39                                              Here we describe a rapid, simple and versatile Free-of-A
40                                              Here we describe a reporter cell-based assay to quantify
41                                              Here we describe a revised PHI-base Version 4 data platf
42                                              Here we describe a role for the RNA processing factors T
43                                              Here we describe a scheme for protecting solid-state qub
44                                              Here we describe a simple and powerful method involving
45                                              Here we describe a simple and reproducible method to gen
46                                              Here we describe a subset of tumor-infiltrating CD8(+) T
47                                              Here we describe a systematic study of cytosine-rich DNA
48                                              Here we describe a technique that improves the spatiotem
49                                              Here we describe a versatile, functional pipeline and ap
50                                              Here, we describe a 3.6 A single-particle cryo-EM recons
51                                              Here, we describe a 3D printed inexpensive open source a
52                                              Here, we describe a case of a presplenectomized 30-year-
53                                              Here, we describe a combined biological/enzymatic synthe
54                                              Here, we describe a complementary gas chromatography-ele
55                                              Here, we describe a computational method, dubbed CAPE, w
56                                              Here, we describe a CRISPR affinity purification in situ
57                                              Here, we describe a CRISPR-based system that uses pairs
58                                              Here, we describe a cross-sectional study where subjects
59                                              Here, we describe a designed dominant negative termed A-
60                                              Here, we describe a dissociation method that uses a prot
61                                              Here, we describe a family with Liddle syndrome due to a
62                                              Here, we describe a function for autophagy in germline s
63                                              Here, we describe a gene expression model, which is repr
64                                              Here, we describe a general approach for predicting pept
65                                              Here, we describe a general approach that we developed t
66                                              Here, we describe a general inverse design algorithm for
67                                              Here, we describe a general method for using radiolabele
68                                              Here, we describe a generalizable platform to create dua
69                                              Here, we describe a generic method to separate the indiv
70                                              Here, we describe a high-throughput method for rapid ide
71                                              Here, we describe a highly parallel, low-cost method for
72                                              Here, we describe a homeostatic regulatory circuit that
73                                              Here, we describe a hybrid platform combining common ana
74                                              Here, we describe a machine learning approach, called HI
75                                              Here, we describe a materials-based approach whereby app
76                                              Here, we describe a mechanism optimizing the performance
77                                              Here, we describe a mechanism that accounts for the abil
78                                              Here, we describe a method for the unbiased, in vivo sel
79                                              Here, we describe a method that allows temporal control
80                                              Here, we describe a method that drastically improves int
81                                              Here, we describe a molecular toolkit for rapid preparat
82                                              Here, we describe a mouse strain lacking the E3 ubiquiti
83                                              Here, we describe a new methodology for a rapid and modu
84                                              Here, we describe a new mouse model suitable for such ri
85                                              Here, we describe a new recombinant PRV expressing a car
86                                              Here, we describe a new role for the ATP-dependent helic
87                                              Here, we describe a novel antiapoptotic mechanism in vas
88                                              Here, we describe a novel approach to stereoselective sy
89                                              Here, we describe a novel cAMP/PKA signalling domain loc
90                                              Here, we describe a novel injury assay in adult Drosophi
91                                              Here, we describe a novel method based on intronic MiMIC
92                                              Here, we describe a novel method that integrates the cov
93                                              Here, we describe a novel method to quantitate and asses
94                                              Here, we describe a novel temporal mechanism of topograp
95                                              Here, we describe a photoredox-assisted catalytic system
96                                              Here, we describe a platform for phenotyping variant lib
97                                              Here, we describe a proof-of-concept for new methodology
98                                              Here, we describe a proteomics approach that identifies
99                                              Here, we describe a protocol for generating and expandin
100                                              Here, we describe a rapid example of dwarfing of a large
101                                              Here, we describe a rapid method for qualitative label-f
102                                              Here, we describe a rapid, inexpensive, and portable str
103                                              Here, we describe a role for CBR1 in metabolism of gluco
104                                              Here, we describe a role for the CTL of Caulobacter cres
105                                              Here, we describe a role of AP2 in promoting the mainten
106                                              Here, we describe a role of LMP1 in EV production that r
107                                              Here, we describe a scalable, spectroscopic approach tha
108                                              Here, we describe a screen for transcription factors (TF
109                                              Here, we describe a second function of PtDd, namely, the
110                                              Here, we describe a self-contained immunoassay platform
111                                              Here, we describe a set of tools to rapidly clone and st
112                                              Here, we describe a similar hypomethylated subtype of lu
113                                              Here, we describe a single-molecule junction comprising
114                                              Here, we describe a single-molecule optical-trapping ass
115                                              Here, we describe a small molecule screen designed to id
116                                              Here, we describe a structure we refer to as the embryo
117                                              Here, we describe a structure-guided development of a se
118                                              Here, we describe a study done in the Lake Superior-Sain
119                                              Here, we describe a system for differentiating PrrF and
120                                              Here, we describe a thorough molecular and biochemical a
121                                              Here, we describe a total of 119 patients with advanced
122                                              Here, we describe a unique role for the orphan catalytic
123                                              Here, we describe A-485, a potent, selective and drug-li
124                                              Here, we described a bnAb lineage targeting the Env V2 a
125                                              Here, we describe AAV-PHP.eB and AAV-PHP.S, capsids that
126                                              Here we describe an alternative strategy for Parkinson's
127                                              Here we describe an antibody mimetic, DARPin K27, which
128                                              Here we describe an approach to functionally validate id
129                                              Here we describe an automated computational framework to
130                                              Here we describe an endogenous Deltaretrovirus, identifi
131                                              Here we describe an enhanced fluorescence fluctuation im
132                                              Here we describe an intercalation compound in which the
133                                              Here we describe an on-demand covalent chemistry to addr
134                                              Here we describe an optimized protocol for simultaneous
135                                              Here we describe an smFISH protocol that allows for the
136                                              Here we describe an unexpected fundamental role for ACKR
137                                              Here we describe an update of the database.
138                                              Here, we describe an algorithm that solves the high erro
139                                              Here, we describe an Amot-dependent complex comprised of
140                                              Here, we describe an approach to cryogenic photoactivate
141                                              Here, we describe an automated clustering approach and a
142                                              Here, we describe an enzymatic/mass spectrometric finger
143                                              Here, we describe an intellectual disability disorder in
144                                              Here, we describe an unexpected role of ATR in mitosis.
145                                              Here, we describe an update of IMG-ABC, which includes C
146                                              Here we describe and compare tasks that tap into these c
147                                              Here we describe and computationally validate a framewor
148                                              Here we describe and functionally characterize a previou
149                                              Here we described and analyzed a similar phenotype in PO
150                                              Here, we describe and compare the brains of a day-active
151                                              Here, we describe and engineer plasmonic substrates base
152                                              Here, we describe assays capable of distinguishing a var
153                                              Here, we describe B cell responses to C-PfCSP from Europ
154                                              Here, we describe bromodomain-containing proteins with d
155                                              Here, we describe cancer-associated genomic profiles fro
156                                              Here we describe chemically-driven artificial rotary and
157                                              Here, we describe ChloroKB, a Web application for visual
158                                              Here we describe clinicopathologic features of Ebola vir
159                                              Here we describe 'coincidence-detecting' sensors that se
160                                              Here, we describe comprehensive adjuvant formulation dev
161                                              Here, we describe crystal and nuclear magnetic resonance
162                                              Here we describe DeActs, genetically encoded actin-modif
163                                              Here, we describe development and characterization of 'S
164                                              Here we describe emerging findings demonstrating that TS
165                                              Here we describe evidence of a negative feedback loop, i
166                                              Here we describe exogenous cycles and endogenous rhythms
167                                              Here we describe experiments in which we studied binocul
168                                              Here, we describe for the first time the expression of s
169                                              Here, we describe functional units, at a cellular level,
170                                              Here we describe genetic effects on gene expression leve
171                                              Here we describe genome-engineering based evaluation of
172                                              Here we describe high-quality draft genomes of these two
173                                              Here we describe how the endothelial transcription facto
174                                              Here we describe how to apply CellNet to RNA-seq data an
175                                              Here, we describe how a specific class of EVs, called mi
176                                              Here, we describe how F-specific antibodies protect agai
177                                              Here, we describe how one can apply solid-state NMR, ran
178                                              Here, we describe how phenotype-to-genotype studies are
179                                              Here, we describe how plasmonic superlattices-finite-arr
180                                              Here, we describe how TBI changes the metabolism of esse
181                                              Here, we describe how to control d by physical confineme
182                                              Here we describe iterative expansion microscopy (iExM),
183                                              Here we describe its intercalation by several alkali met
184                                              Here, we describe Leapfrog, a simple automated BLAST pip
185                                              Here we describe Mackinac, a Python package that combine
186                                              Here we describe manipulation of the X. laevis genome us
187                                              Here we describe methodology permitting fusion gene cons
188                                              Here, we describe mGluR5 findings in stress disorders, p
189                                              Here, we describe micro-patterned all-polymer films call
190                                              Here, we describe molecular force microscopy, leveraging
191                                              Here, we describe motor cortical changes in a visuomotor
192                                              Here, we describe mutations in DZIP1L, which encodes DAZ
193                                              Here we describe networks of capacitating genetic intera
194                                              Here, we describe NGSCheckMate, a user-friendly software
195                                              Here, we describe NicE-seq (nicking enzyme assisted sequ
196                                              Here, we describe Nol12 as a multifunctional RBP with ro
197                                              Here we describe novel interactions between HSV-1 and th
198                                              Here we describe our protocol for correlated cryo-fLM, c
199                                              Here, we describe our approach to monitoring BMT survivo
200                                              Here, we describe potential biases that arise when ABM a
201                                              Here, we describe pyocyanin demethylase (PodA), a hither
202                                              Here we describe RCB-185, a lipophilic prodrug with nano
203                                              Here we describe "semisynthetic" pH-sensitive protein co
204                                              Here we describe sex differentiation in a wild grayling
205                                              Here we describe SGN-CD19B, a pyrrolobenzodiazepine (PBD
206                                              Here we describe ShootingStar, a platform for perturbati
207                                              Here, we describe site-selective, copper-promoted coupli
208                                              Here, we describe sleep and activity in two neighbouring
209                                              Here we describe small target-selective neurons in preda
210                                              Here we describe spectacular extremely expanded, pod-lik
211                                              Here, we describe structural elements called interface a
212                                              Here, we describe such a method for elucidating drug res
213                                              Here, we describe such a method in a 96-well plate forma
214                                              Here, we describe that low catalyst loadings (0.27 mol %
215                                              Here we describe the 'Asgard' superphylum, a group of un
216                                              Here we describe the ability of paclitaxel (PTX), a fron
217                                              Here we describe the assembly, physical characteristics,
218                                              Here we describe the correction of the heterozygous MYBP
219                                              Here we describe the crystal structure of GS-5745.MMP9 c
220                                              Here we describe the design, discovery, pharmacologic ac
221                                              Here we describe the development of a point-of-care sens
222                                              Here we describe the development of a simple, low-cost,
223                                              Here we describe the efficacy of a HIF-1alpha inhibitor,
224                                              Here we describe the fabrication of a sub-micrometer ele
225                                              Here we describe the first phosphorylation event involvi
226                                              Here we describe the first stages of kidney vascularisat
227                                              Here we describe the identification of gamma-activated s
228                                              Here we describe the importance of mRNA translational re
229                                              Here we describe the interaction of myosin-5B with F-act
230                                              Here we describe the isolation and characterization of a
231                                              Here we describe the pathways of host-parasite interacti
232                                              Here we describe the purification of a neurotoxin precur
233                                              Here we describe the rational development of new molecul
234                                              Here we describe the reconstitution of Pol epsilon-depen
235                                              Here we describe the results in a cohort of 10 stable ki
236                                              Here we describe the results of a systematic study inves
237                                              Here we describe the science that supports this novel th
238                                              Here we describe the sequence assembly and analysis of t
239                                              Here we describe the shotgun-sequencing of ancient DNA f
240                                              Here we describe the stabilization of the heaviest 4+ io
241                                              Here we describe the temporal orchestration of a series
242                                              Here we describe the tranSMART-XNAT Connector we have de
243                                              Here we describe the use of a mechanism-based inhibitor,
244                                              Here we describe the use of Hi-C as a tool for detection
245                                              Here we describe the use of walking loops in parks and c
246                                              Here we describe the utility of peptide macrocyclization
247                                              Here, we describe the capabilities of another activation
248                                              Here, we describe the central role of inflammatory caspa
249                                              Here, we describe the circuit architecture of the visual
250                                              Here, we describe the construction and use of the Activi
251                                              Here, we describe the construction of supramolecular pol
252                                              Here, we describe the course and provide resources for d
253                                              Here, we describe the crystal structure of PRL-1 in comp
254                                              Here, we describe the crystal structure of the Gn glycop
255                                              Here, we describe the design and discovery of novel clas
256                                              Here, we describe the design and synthesis of an ITPA-sp
257                                              Here, we describe the development and preclinical evalua
258                                              Here, we describe the development of a flexible thin-fil
259                                              Here, we describe the development of a generalized linea
260                                              Here, we describe the development of a programmable CRIS
261                                              Here, we describe the development of a tiered museum-bas
262                                              Here, we describe the development of an alternative vacc
263                                              Here, we describe the development of the first chemilumi
264                                              Here, we describe the discovery of a splice isoform-depe
265                                              Here, we describe the discovery of the most potent inhib
266                                              Here, we describe the engineering of a light-activated h
267                                              Here, we describe the fabrication, testing and first fie
268                                              Here, we describe the FEP+ method as applied to protein
269                                              Here, we describe the first activating mutation in the f
270                                              Here, we describe the function of the plant homeodomain
271  major mosquito disease vector Aedes aegypti Here, we describe the generation of multiple stable, tra
272                                              Here, we describe the generation of transgenic, inducibl
273                                              Here, we describe the identification of Ms1, a gene prop
274                                              Here, we describe the latest database release, the IPD-M
275                                              Here, we describe the map-based cloning of the Ms2 gene
276                                              Here, we describe the mechanism of action of the previou
277                                              Here, we describe the mode of action of bimagrumab (BYM3
278                                              Here, we describe the nature and comparative reactivity
279                                              Here, we describe the near-atomic resolution structure o
280                                              Here, we describe the optimization of the 2-anilino quin
281                                              Here, we describe the rapid and selective thionation of
282                                              Here, we describe the recent improvements in IRD includi
283                                              Here, we describe the somatic acquisition of promoter mu
284                                              Here, we describe the surgical, immunological, and neuro
285                                              Here, we describe the use of a combined method including
286                                              Here, we describe the use of fluorescence recovery after
287                                              Here, we describe the use of PRO-seq to characterize the
288                                              Here, we describe the use of side-group chemistry to con
289                                              Here, we describe the use of the B. subtilis model syste
290                                              Here, we describe the WHO-coordinated laboratory network
291  ongoing studies where clade C predominates, here we describe three virus panels, chosen from 200 wel
292                                              Here, we describe three examples to establish that the a
293                                              Here we describe two advances that address these limitat
294                                              Here we describe two multi MCE domain-containing protein
295                                              Here, we describe two brothers with hematopoietic and im
296                                              Here, we describe two resources developed by the KMC: th
297                                              Here, we describe two strategies that successfully inves
298                                              Here, we describe type 2 innate lymphocytes (ILC2s) as a
299                                              Here we describe utilization of a surface motif exchange
300                                              Here, we describe why a shared approach to treatment dec

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top